research Experience with oral tofacitinib in two adolescents and seven adults with alopecia areata
Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.
Search
for
Sort by
Research
240-270 / 1000+ results research Real‐World Efficacy and Safety of Tofacitinib for Patients With Alopecia Areata: A Retrospective Multi‐Center Cohort Study
Tofacitinib effectively treats severe alopecia areata, improving hair regrowth and patient satisfaction.
research Intralesional betamethasone versus triamcinolone acetonide in the treatment of localized alopecia areata: a within-patient randomized controlled trial
Triamcinolone acetonide is slightly more effective than betamethasone for hair regrowth in localized alopecia areata.
research Enhancing hair regrowth in Alopecia areata: the power duo of CO2 fractional laser and Bimatoprost
Combining CO2 laser and Bimatoprost effectively boosts hair regrowth in Alopecia Areata.
research Baricitinib as the first systemic treatment for severe alopecia areata
Baricitinib is effective as a treatment for severe hair loss.
research Trichoscopic evaluation in oral tofacitinib and oral betamethasone in the treatment of moderate to severe alopecia areata
Oral betamethasone works faster than oral tofacitinib for hair regrowth in alopecia areata.
research Identification of novel step‐up regimen of intralesional triamcinolone acetonide in scalp alopecia areata based on a double‐blind randomized controlled trial
Start with 2.5 mg/mL triamcinolone acetonide for scalp alopecia areata and increase if needed.
research Nanostructured lipid carriers loaded with an association of minoxidil and latanoprost for targeted topical therapy of alopecia
A new treatment for hair loss uses tiny lipid carriers to deliver a mix of minoxidil and latanoprost directly to hair follicles, promoting hair growth and being well tolerated by the skin.
research Effectiveness and safety of baricitinib in patients with moderate‐to‐severe refractory alopecia areata in real world: An open‐label, single‐center study
Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.
research Evaluation of the Efficacy and Safety of Oral Tofacitinib for the Treatment of Alopecia Areata in Children
Tofacitinib effectively reduces hair loss in children with alopecia areata but may cause mild side effects and relapses.
research BH06 (P075) A randomized controlled trial comparing the efficacy and safety of oral tofacitinib vs. methotrexate in moderate-to-severe alopecia areata
Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.
research Efficacy and Safety of Tofacitinib in Paediatric Alopecia Aerata - A Prospective Observational Study
Tofacitinib effectively promotes hair regrowth in children with alopecia areata, but more research on long-term safety is needed.
research Fractional ablative CO2 laser and oral isotretinoin—A prospective randomized controlled split‐face trial comparing concurrent versus delayed laser treatment for acne scars
Concurrent laser and isotretinoin treatment improves acne scars more than delayed treatment.
research [Advances in topical therapy of skin diseases (author's transl)].
New treatments for skin diseases in 1979 showed promising results with fewer side effects.
research Alopecia universalis. Partial response to tofacitinib
Tofacitinib partially improved hair regrowth in a patient with severe hair loss.
research Baricitinib for the Treatment of Moderate-to-Severe Alopecia Areata
Baricitinib helps regrow hair in severe alopecia areata and is safe, but more research is needed.
research Tofacitinib for the Treatment of Three Immune-mediated Conditions in One Patient: Ulcerative Colitis, Pyoderma Gangrenosum, and Alopecia Areata
Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.
research Alopecia areata treated using CO2 fractional laser with different parameters
CO2 fractional laser treatment helped regrow hair in a 13-year-old with alopecia areata.
research Extemporaneous Topical Minoxidil Solutions for the Treatment of Androgenetic Alopecia- Stability Studies and Incorporation Tests of Active Pharmaceutical Ingredients in Aloplus Total Base.
The new minoxidil lotion using Aloplus Total is stable and can be mixed with other ingredients for treating hair loss.
research Ruxolitinib 1.5% Topical Cream for the Treatment of Pediatric Alopecia Areata
Ruxolitinib cream may help treat severe hair loss in children.
research Experience in treating multifocal alopecia areata in a child with Jak kinase inhibitors
JAK inhibitors like tofacitinib may effectively treat alopecia in children without major side effects.
research The role of oclacitinib in the management of ischaemic dermatopathy in four dogs
Oclacitinib effectively treated a skin condition in dogs that didn't respond to other immunosuppressants.
research Off-Label Treatment of Alopecia Areata—Retrospective Study
Off-label treatments are heavily used for alopecia areata due to limited approved options.
research Efficacy and predictive markers of response to tofacitinib and baricitinib therapy in alopecia areata: A 52-week comparative cohort study
Tofacitinib and baricitinib are similarly effective and safe for alopecia areata, but baricitinib works faster.
research Oral tofacitinib monotherapy in Korean patients with refractory moderate-to-severe alopecia areata: A case series
Tofacitinib is effective and safe for treating severe hair loss in Korean patients.
research The Efficacy of Intralesional Pentoxifylline Injection versus the Standard Intralesional Corticosteroid Injection in The Treatment of Alopecia Areata
Combining pentoxifylline with corticosteroids improves alopecia areata treatment.
research Treatment of severe alopecia areata with intralesional steroid injections.
Intralesional steroid injections are safe and effective for treating severe alopecia areata.
research 277 An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata
Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.
research A randomized, blinded, three-arm, multicenter trial comparing the efficacy and safety of fluconazole given once daily for 3 or 6 weeks with griseofulvin given once daily for 6 weeks in pediatric patients with tinea capitis
The two lotions used day and night may be a good alternative to minoxidil for hair loss treatment with better cosmetic effects and tolerance.
research Efficacité à long terme du baricitinib dans le traitement de la pelade : résultats à la semaine 104 des études BRAVE-AA1 et BRAVE-AA2
Baricitinib effectively treats severe alopecia for up to 104 weeks.